<DOC>
	<DOCNO>NCT01767987</DOCNO>
	<brief_summary>The investigator test upfront dose Ranolazine reduce myocardial biomarker release ( CK-MB , Troponin ) post percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>Ranolazine Cardioprotection PCI</brief_title>
	<detailed_description>Ranolazine demonstrate decrease angina , ischemia perfusion imaging , improve diastolic function , cardiac metabolism . Furthermore associated reduce cardiac arrhythmia , include non-sustained ventricular tachycardia atrial fibrillation . It study acute cardioprotective agent percutaneous coronary intervention ( PCI ) . We hypothesize upfront administration Ranolazine could decrease myocardial injury associate PCI due factor list ( i.e . precondition myocardium ) . We plan screen patient schedule elective coronary angiogram . Those meet criterion consent randomize either receive Ranolazine placebo twice day 3 day lead PCI .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Age 18 old Patients undergo Coronary Angiography possible PCI Able willing give consent Able read write English Current EKG Biomarker Acute Myocardial Infarction ( MI ) Acute Coronary Syndromes ( ACS ) History Allergy Ranolazine Pregnant Nursing Currently take Ranolazine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>ACS</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>PCI</keyword>
	<keyword>Ranolazine</keyword>
	<keyword>Coronary Angiogram</keyword>
	<keyword>Cardioprotectant</keyword>
</DOC>